OBJECTIVES: To assess the budget impact implication of introducing adalimumab biosimilars across Belgium for all licensed adult adalimumab indications.

METHODS: A budget-impact model was used to estimate the cost saving potential of introducing an adalimumab biosimilar vs the reference biologic in Belgium over a one- and two-year time horizon from a payer’s perspective. Current adalimumab treated populations were estimated through IMS sales data and the population was assumed to remain constant during the 2-year horizon.

Modelled scenarios were developed for an adalimumab biosimilar vs the reference biologic product at two discounted prices (20% and 30%) as well as the potential cost saving opportunity with immediate transition of 30% and 40% of the market. Uptake was assumed to be linear over the timeframes.

RESULTS: Introduction of adalimumab biosimilars into the biologic treatment algorithm over a one- and two-year linear uptake timeframe, with a resulting market share of approximately 16% and 22% at completion could result in projected budget-savings of €15m, €20.5m, €20m and €27m respectively.

An immediate switch of 30% and 40% of the market at 20% and 30% price discounting could release potential savings of approximately €14m, €19m, €21m and €28m respectively.

CONCLUSIONS: The introduction of adalimumab biosimilars represents a significant cost-saving opportunity within the Belgian healthcare system. Anti-TNFs are the most commonly prescribed biologics in rheumatologic, gastroenterological and dermatological immune diseases within Belgium. Savings could be used to treat additional patients within the same therapeutic areas, meet funding requirement for new high cost therapies within high mortality risk disease areas, and/or potentially support additional funding for enhanced clinical resources. Mechanisms in place that can support the biosimilar uptake are essential in order to achieve these savings.